[{"orgOrder":0,"company":"Starpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Patent Issued For DEP\u00ae Cabazitaxel Nanoparticle","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabazitaxel","moa":"Tubulin alpha-4A chain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Starpharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Starpharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Starpharma \/ Not Applicable"},{"orgOrder":0,"company":"Starpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starpharma Releases Positive DEP\u00ae phase 2 Interim Results in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabazitaxel","moa":"Tubulin alpha-4A chain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Starpharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Starpharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Starpharma \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natco Pharma's Partner Breckenridge Gets FDA Nod for Prostate Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabazitaxel","moa":"Microtubule","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Natco","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Natco"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Approval of its ANDA for Cabazitaxel Intravenous Solution (Generic for Jevtana Kit\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabazitaxel","moa":"Microtubule","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVER Pharma gains EU marketing authorization for value-added Cabazitaxel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabazitaxel","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Ever Pharma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Ever Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$201.3 million","upfrontCash":"Undisclosed","newsHeadline":"Xencor Closes Public Offering with Full Exercise of Underwriters' Option","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Cabazitaxel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Xencor","amount2":0.20000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Leerink Partners","highestDevelopmentStatusID":null,"companyTruncated":"Xencor \/ Leerink Partners"}]
Find Clinical Drug Pipeline Developments & Deals for TXD258
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
